<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993798</url>
  </required_header>
  <id_info>
    <org_study_id>BU-002-IM</org_study_id>
    <nct_id>NCT00993798</nct_id>
  </id_info>
  <brief_title>An International Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery</brief_title>
  <official_title>An International, Randomised, Double Blinded, Multi-centre, Active- and Placebo-controlled Dose Response Trial to Evaluate the Efficacy and Safety of SABER-Bupivacaine for Postoperative Pain Control in Patients Following Arthroscopic Shoulder Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durect</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durect</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to identify the optimal dose of SABER-Bupivacaine for postoperative pain
      control in patients undergoing elective arthroscopic shoulder surgery on the basis of
      pharmacokinetics, efficacy and safety evaluations. The study duration consists of a screening
      period up to 14 days and a treatment period 14 days with a long term follow up visit at 6
      months. The study will provide further data on safety.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity (PI)</measure>
    <time_frame>0-3 days after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Supplemental opioid use</measure>
    <time_frame>0-3 days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to first opioid rescue medication usage</measure>
    <time_frame>0-14 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of opioid related side effects</measure>
    <time_frame>0-7 days after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>SABER-Bupivacaine Treatment 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 1b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl Treatment 1c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SABER-Bupivacaine Treatment 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 2b</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine HCl Treatment 2c</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>double-blind</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine Treatment 1a</intervention_name>
    <description>5.0 ml</description>
    <arm_group_label>SABER-Bupivacaine Treatment 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SABER-Bupivacaine Treatment 1b</intervention_name>
    <description>5.0 ml</description>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl Treatment 1c</intervention_name>
    <description>20.0 ml</description>
    <arm_group_label>Bupivacaine HCl Treatment 1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SABER-Bupivacaine Treatment 2a</intervention_name>
    <description>7.5 ml</description>
    <arm_group_label>SABER-Bupivacaine Treatment 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo SABER-Bupivacaine Treatment 2b</intervention_name>
    <description>7.5 ml</description>
    <arm_group_label>Placebo SABER-Bupivacaine Treatment 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine HCl Treatment 2c</intervention_name>
    <description>20.0 ml</description>
    <arm_group_label>Bupivacaine HCl Treatment 2c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subacromial impingement syndrome

          -  MRI with intact rotator cuff

          -  Patients suitable for general anaesthesia

        Exclusion Criteria:

          -  Known major joint trauma, infection, avascular necrosis, chronic dislocation,
             inflammatory or degenerative glenohumeral arthropathy, glenohumeral arthritis, frozen
             shoulder or previous surgery of the affected shoulder

          -  Abnormal ECG

          -  Prolonged QT syndrome

          -  Current or regular use of analgesic medication for other indication(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nycomed Clinical Trial Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Headquarters</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Skoerping</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nycomed Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <disposition_first_submitted>January 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>January 23, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 29, 2013</disposition_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post operative pain</keyword>
  <keyword>Local anaesthesia</keyword>
  <keyword>Postoperative pain after arthroscopic shoulder surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

